Open an account

BioCryst Pharmaceuticals

BCRX · NASDAQ

$7.94−$0.13 (−1.61%)TodayMarket closed ·
Prev close $8.07

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 435 full-time employees. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. The company has also obtained an early-stage program for atopic dermatitis, STAR0310.

Employees
435
Headquarters
Durham, North Carolina
Listed
Mar 4, 1994
Sector
Health Care
Industry
Biotechnology
Website
biocryst.com

BCRX key statistics

Market cap
2.03B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.15M
Volume
8.44M
Open price
$8.11
High today
$8.13
Low today
$7.84
52 Week high
$11.22
52 Week low
$6.23

BioCryst Pharmaceuticals (BCRX) at a glance

BioCryst Pharmaceuticals (BCRX) last traded at $7.94, with a market cap of 2.03B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $7.84 and $8.13. The current price is 1.3% above the day's low and 2.3% below its high.

Volume so far is 8.44M shares, above the average of 5.15M shares a day.

Over the past year BioCryst Pharmaceuticals has ranged from $6.23 to $11.22, and now sits 34% of the way up that range.

BioCryst Pharmaceuticals met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.30 per share against an estimate of $0.1209.

The average analyst price target is $21.93, 176.2% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

63%of 8 analyst ratings say Buy
  • Buy62.5%
  • Hold37.5%
  • Sell0.0%
Price target · 13 analystsAvg $21.93
Low
$11.11
Now
$7.94
High
$33.60

BCRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 123.7% on average.

  1. Q3 FY24: reported -$0.07 per share against an estimate of -$0.0657
  2. Q4 FY24: reported -$0.13 per share against an estimate of -$0.0581
  3. Q1 FY25: reported $0.00 per share against an estimate of -$0.0695
  4. Q2 FY25: reported $0.04 per share against an estimate of $0.0143
  5. Q3 FY25: reported $0.06 per share against an estimate of $0.0359
  6. Q4 FY25: reported $0.01 per share against an estimate of $0.0386
  7. Q1 FY26: reported -$0.09 per share against an estimate of $0.0495
  8. Q2 FY26: reported $0.30 per share against an estimate of $0.1209

BCRX news

  • Full Transcript: BioCryst Pharma Q1 2026 Earnings Call

  • Press releasePRNewswire

    Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

  • Vandana Singh

    BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug

  • Press releaseBusiness Wire

    Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

  • Erica Kollmann

    Top Stocks With Earnings This Week: Joby, IonQ, AMD and More

  • Press releaseBusiness Wire

    Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

  • Press releaseBusiness Wire

    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

  • Vandana Singh

    Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

Similar companies

Companies in the same industry as BioCryst Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.